certican 0,5 mg tabletid tablett
novartis baltics sia - everoliimus - tablett - 0,5mg 50tk; 0,5mg 100tk; 0,5mg 250tk; 0,5mg 60tk
certican 0,25 mg dispergeeruvad tabletid dispergeeruv tablett
novartis baltics sia - everoliimus - dispergeeruv tablett - 0,25mg 100tk; 0,25mg 60tk; 0,25mg 50tk; 0,25mg 250tk
tachyben infusioonilahuse kontsentraat
ever neuro pharma gmbh - urapidiil - infusioonilahuse kontsentraat - 5mg 1ml 20ml 5tk
dacepton 10 mg/ml süste-/infusioonilahus
ever neuro pharma gmbh - apomorfiin - süste-/infusioonilahus - 10mg 1ml 5ml 5tk; 10mg 1ml 5ml 10tk; 10mg 1ml 5ml 50tk; 10mg 1ml 5ml 25tk; 10mg 1ml 5ml 30tk
dacepton 5 mg/ml infusioonilahus
ever neuro pharma gmbh - apomorfiin - infusioonilahus - 5mg 1ml 20ml 1tk; 5mg 1ml 20ml 10tk; 5mg 1ml 20ml 30tk; 5mg 1ml 20ml 5tk
tachyben süstelahus
ever neuro pharma gmbh - urapidiil - süstelahus - 5mg 1ml 10ml 5tk
tachyben süstelahus
ever neuro pharma gmbh - urapidiil - süstelahus - 5mg 1ml 5ml 5tk
certican dispergeeruv tablett
novartis farmaceutica s.a. - everoliimus - dispergeeruv tablett - 0,25mg 100tk
kisplyx
eisai gmbh - lenvatinibmesülaat - kartsinoom, neerurakk - antineoplastilised ained - kisplyx is indicated for the treatment of adults with advanced renal cell carcinoma (rcc):in combination with pembrolizumab, as first-line treatment (see section 5. in combination with everolimus, following one prior vascular endothelial growth factor (vegf)-targeted therapy.
prepalepan infusioonilahus
ever neuro pharma gmbh - levetiratsetaam - infusioonilahus - 15mg 1ml 100ml 10tk